Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ICTCAR-TC is a preclinical-stage chimeric antigen receptor (CAR) T-cell therapy developed by SiDanSai Biotechnology (ICT) for the treatment of thyroid cancer. The therapy utilizes the company's proprietary CoupledCAR® platform, which is designed to enhance the expansion and infiltration of CAR-T cells into solid tumors. ICTCAR-TC specifically targets the Thyroid Stimulating Hormone Receptor (TSHR), a protein frequently overexpressed in thyroid malignancies. By leveraging the CoupledCAR® technology, the therapy aims to overcome the immunosuppressive microenvironment of solid tumors, potentially providing a more effective treatment option for patients with advanced thyroid cancer.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ICTCAR-TC.